Form 8-K - Current report:
SEC Accession No. 0001104659-25-058893
Filing Date
2025-06-12
Accepted
2025-06-12 16:19:54
Documents
12
Period of Report
2025-06-12
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2517877d1_8k.htm   iXBRL 8-K 33882
  Complete submission text file 0001104659-25-058893.txt   201324

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA bdtx-20250612.xsd EX-101.SCH 3062
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE bdtx-20250612_lab.xml EX-101.LAB 34239
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bdtx-20250612_pre.xml EX-101.PRE 22390
14 EXTRACTED XBRL INSTANCE DOCUMENT tm2517877d1_8k_htm.xml XML 3700
Mailing Address ONE MAIN STREET, 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE MAIN STREET, 14TH FLOOR CAMBRIDGE MA 02142 617-417-5868
Black Diamond Therapeutics, Inc. (Filer) CIK: 0001701541 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39200 | Film No.: 251042905
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)